LOUISVILLE, Ky. (WDRB) — A bill to ban machine gun conversion devices, also known as switches, advanced in Frankfort Tuesday.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...

Although fluid restriction is standard first-line treatment, it is often ineffective in patients with hyponatremia and syndrome of inappropriate antidiuresis (SIAD).

This one-day decline has now brought NVO’s twelve-month return to -56%. The pertinent question: Is this a buying opportunity?

Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical ...

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...

Welcome to the February 2026 edition of the 'junior' lithium miner news. We have categorized those lithium miners that are ...

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...

Sable Resources Ltd. ("Sable" or the "Company") (TSXV: SAE | OTCQB: SBLRF) is pleased to report the discovery of a new copper ...